Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.

Several dermoscopic findings may help identify low-grade dysplastic nevi from other lesions, though the performance of the methods used was poor.